Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1 injection in locally advanced or metastatic chordoma
CTR20250195Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in chordoma, sponsored by Biokin Pharmaceutical. Started Feb 2025; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
chordoma
Beyond the preview
Go deeper on CTR20250195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250195.